All patients with transfusion-dependent β-thalassemia and a non-β0/β0 genotype who achieved transfusion independence continue to maintain it for up to 3.5 years in Phase 1/2 Northstar (HGB-204) study
HbAT87Q levels were stable and vaso-occlusive events were reduced in most Group A and B patients with sickle cell disease in Phase 1/2 HGB-206 study following treatment with LentiGlobin
“The breadth of our LentiGlobin data at ASH across multiple clinical
trials reflects the commitment of patients, families and healthcare
providers to investigate the transformative therapeutic potential of
gene therapy for the beta-hemoglobinopathies,” said
LentiGlobin in Transfusion-Dependent β-Thalassemia
TDT is an
inherited blood disorder caused by a mutation in the β-globin gene,
which causes ineffective red blood cell production leading to severe
anemia. People with TDT require regular transfusions to maintain
hemoglobin levels in order to survive, but chronic transfusions carry
risks, including iron overload that can result in multi-organ damage and
shortened life expectancy.
“The Northstar study includes patients who have been transfusion
independent for more than three and a half years after receiving
LentiGlobin treatment,” said Dr.
Phase 1/2 Northstar (HGB-204) Efficacy
The results reported
for the completed Phase 1/2 Northstar (HGB-204) study reflect data as of
After treatment with LentiGlobin, patients are monitored for production of HbAT87Q, which is gene therapy derived-hemoglobin. The production of HbAT87Q increases the overall hemoglobin level in patients with the goal of reducing or eliminating the need for transfusions.
Data showed that eight of 10 patients with TDT and a non-β0/β0
genotype who were treated with LentiGlobin in the Northstar study
achieved transfusion independence, meaning they had not received a
transfusion for at least 12 months and maintained hemoglobin >9 g/dL.
These eight patients have maintained transfusion independence for a
median duration of 38 months (21 – 44 months) as of
Total hemoglobin levels for the eight transfusion-independent non-β0/β0 genotype patients were stable and ranged from 9.7 – 14.1 g/dL at the last study visit. HbAT87Q remained stable in these patients over time, for up to four years as of the time of data cut-off.
Three of the eight patients with TDT and a β0/β0 genotype who were treated with LentiGlobin achieved transfusion independence. Two of these patients had follow-up for more than 3.5 years and one had more than two years of follow up. All three maintained transfusion independence through their last follow up with hemoglobin ranging from 9.1 – 10.9 g/dL.
An exploratory assessment was conducted to assess liver iron concentration in the 11 patients who have become transfusion independent in the Northstar study. Increased iron levels are a consequence of frequent transfusions. High iron levels can cause organ damage, which many TDT patients are at risk for and must manage through chelation regimens. Liver iron concentrations were measured at baseline and then at every 12 months after treatment. Over time, iron concentrations began to decrease in the 11 patients, with the largest decrease observed in patients who had 48 months (n=3) of data available.
Phase 1/2 Northstar (HGB-204) Safety
The safety profile of
LentiGlobin treatment in adults and adolescents with TDT in the
Northstar study was generally consistent with myeloablative
conditioning. The median time to platelet engraftment was 39.5 (19 –
191) days.
In the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies,
a refined manufacturing process was used to produce LentiGlobin to
further improve the clinical results observed in the Northstar study.
Data from Northstar-2 and Northstar-3 studies will be presented on
- LentiGlobin Gene Therapy for Patients with Transfusion-Dependent
β-thalassemia (TDT): Results from the Phase 3 Northstar-2 and
Northstar-3 Studies (Abstract #1025)
Presenter:Franco Locatelli , M.D., Ph.D., Professor of Pediatrics,University of Pavia ,Italy and Director,Department of Pediatric Hematology and Oncology , IRCCS Ospedale Pediatrico Bambino Gesù,Rome, Italy
For more information about the ongoing clinical studies of LentiGlobin in TDT visit www.northstarclinicalstudies.com or clinicaltrials.gov and use identifier NCT02906202 for Northstar-2 (HGB-207) and NCT03207009 for Northstar-3 (HGB-212).
LentiGlobin in Sickle Cell Disease
SCD is a serious,
progressively debilitating and life-threatening genetic disease. SCD
results from production of abnormal sickle hemoglobin (HbS), which leads
to sickled red blood cells (RBCs) and hemolysis. As a result of this
abnormal hemoglobin, many affected individuals live with severe anemia
and vaso-occlusive events (VOE) which include severe, recurrent pain
crises that lead to organ damage and shortened life span.
“In patients with sickle cell disease who underwent autologous
transplant with LentiGlobin, gene therapy-derived HbAT87Q
levels have remained stable and we saw decreased rates of vaso-occlusive
events with up to three years of follow-up,” said Dr.
The Phase 1/2 HGB-206 study is an ongoing, open-label study designed to evaluate the efficacy and safety of LentiGlobin gene therapy for the treatment of adults with SCD.
HGB-206: Groups A & B Efficacy
A total of nine patients
were treated with LentiGlobin in Groups A (n=7) and B (n=2) in the
HGB-206 study. As of the data cut-off date of
In Group A patients, consistent HbAT87Q production was observed ranging from 0.7 – 2.8 g/dL at last visit and patients maintained stable total hemoglobin levels ranging from 7.6 – 11.8 g/dL at last visit. HbAT87Q production was higher in Group B patients, ranging from 3.4 – 6.5 g/dL and total hemoglobin levels were stable at 11.0 – 12.3 g/dL at the last visit. These higher rates of total hemoglobin and HbAT87Q production in Group B are attributed to the implementation of a refined drug product manufacturing process and protocol modifications to improve engraftment of genetically modified stem cells.
In all patients who received LentiGlobin treatment, frequency of VOEs was reduced.
HGB-206: Groups A & B Safety
The safety profile of
LentiGlobin remains generally consistent with underlying SCD and
myeloablative conditioning. A serious adverse event (SAE) of
myelodysplasia syndrome was reported in a patient who received
LentiGlobin approximately three years ago in Group A of the Phase 1/2
HGB-206 study. Analysis of the patient’s cells showed no evidence of
vector mediated insertional oncogenesis, and the independent data
monitoring committees, along with the treating physician, agreed the SAE
was unlikely related to LentiGlobin gene therapy.
In order to further improve the clinical results observed in Groups A
and B, in addition to the refined manufacturing process introduced in
Group B, plerixafor mobilization and apheresis-derived hematopoietic
stem cells were used to produce LentiGlobin for Group C of the Phase 1/2
HGB-206 study. Data from Group C patients will be presented
- Current Results of LentiGlobin Gene Therapy in Patients with Severe
Sickle Cell Disease Treated Under Refined Protocol (Abstract #1026)
Presenter:John Tisdale , M.D., National Heart,Lung and Blood Institute ,Bethesda, Md.
For more information about the ongoing HGB-206 clinical study of LentiGlobin in SCD visit clinicaltrials.gov and use identifier NCT02140554.
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built a pipeline with broad potential application in
severe genetic diseases and cancer.
bluebird bio's gene therapy clinical programs include investigational treatments for cerebral adrenoleukodystrophy, transfusion-dependent β-thalassemia and sickle cell disease.
bluebird bio's oncology pipeline is built upon the company's lentiviral
gene delivery and T cell engineering, with a focus on developing novel T
cell-based immunotherapies, including chimeric antigen receptor (CAR T)
and T cell receptor (TCR) therapies. The company’s lead oncology
programs are anti-BCMA CAR T programs partnered with
bluebird bio’s discovery research programs include utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company's pipeline.
bluebird bio has operations in
Follow bluebird bio on social media: Twitter,
LinkedIn,
Instagram,
LentiGlobin is a trademark of bluebird bio, Inc.
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s views with respect to the potential for its LentiGlobin
product candidate to treat transfusion-dependent β-thalassemia and
sickle cell disease. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks that the preliminary positive efficacy
and safety results from our prior and ongoing clinical trials of
LentiGlobin will not continue or be repeated in our ongoing or planned
clinical trials of LentiGlobin, the risks that the changes we have made
in the LentiGlobin manufacturing will not result in improved patient
outcomes, risks that the current or planned clinical trials of
LentiGlobin will be insufficient to support future regulatory
submissions or to support marketing approval in the US and EU, and the
risk that LentiGlobin will not be successfully developed, approved or
commercialized for the treatment of either transfusion-dependent
β-thalassemia or sickle cell disease. For a discussion of other risks
and uncertainties, and other important factors, any of which could cause
our actual results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in our most recent
Form 10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20181201005010/en/
Source: bluebird bio, Inc.
Investors:
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
or
Media:
Catherine
Falcetti, 339-499-9436
cfalcetti@bluebirdbio.com